Cholesterol, ApoB & Lp(a)
Triglycerides and Healthy Aging
Under 150 mg/dL is the fasting reference. Above it, triglycerides flag heart risk; above 500, pancreatitis. Lowering them alone hasn't reliably cut events.
Triglycerides sit on nearly every routine lipid panel, usually just below the cholesterol numbers people have learned to watch. They’re the supporting actor of the lipid panel: always in the credits, rarely the one anyone asks about. If you’re reading about triglycerides and healthy aging, Humanic Blue has two questions: what is your number telling you, and what can changing it actually do? We followed the number up the guideline’s own ladder to find out.
In plain terms, a fasting triglyceride level under 150 mg/dL is the standard healthy range, according to MedlinePlus from the U.S. National Library of Medicine. The 2026 ACC/AHA multisociety dyslipidemia guideline treats persistently high triglycerides as part of assessing heart and blood-vessel risk. It keeps statins, medicines that lower LDL cholesterol, as the foundation of drug treatment for risk from plaque buildup in arteries, rather than focusing only on lowering triglycerides. At very high levels, particularly 1,000 mg/dL or more, preventing acute pancreatitis becomes a priority. For living longer and better, triglycerides are a warning light whose meaning depends on the particles carrying fat through the blood, the person’s overall risk and how high the result is.
Key Takeaways
- MedlinePlus lists fasting triglycerides under 150 mg/dL as the healthy reference range; there is no established special longevity target below that.
- Large population studies link higher triglycerides with more heart attacks, disease from reduced blood supply to the heart and deaths. They do not establish that triglycerides alone caused those outcomes.
- Very high triglycerides raise the risk of acute pancreatitis, inflammation of the pancreas. The 2026 guideline emphasizes prevention especially at 1,000 mg/dL or more.
- Two major modern trials of fibrates, a class of triglyceride-lowering medicines, did not reduce cardiovascular events overall in people with diabetes. That is not a verdict on every fibrate trial or subgroup.
- No study cited here establishes that lowering triglycerides extends human lifespan.
What does the triglyceride ladder on your lab report show?
The number arrives in milligrams per deciliter (mg/dL) in the US and millimoles per liter (mmol/L) in much of the world. MedlinePlus lists the adult fasting categories:
| Fasting triglycerides | MedlinePlus category | What the 2026 US guideline focuses on |
|---|---|---|
| Under 150 mg/dL (1.7 mmol/L) | Healthy | Routine risk assessment |
| 150–199 mg/dL | Borderline high | Lifestyle and overall risk assessment |
| 200–499 mg/dL | High | Overall cardiovascular risk; ApoB may reveal risk not captured by LDL cholesterol |
| 500–999 mg/dL | Very high | Cardiovascular risk and pancreatitis risk |
| 1,000 mg/dL (11.3 mmol/L) or more | Very high | Pancreatitis prevention first |
Triglycerides are the body’s main storage fat. They travel in the blood inside lipoprotein particles, carriers made of fat and protein. LDL, often called “bad cholesterol,” is one kind of carrier. ApoB is a protein on particles that can contribute to plaque buildup; measuring it helps estimate how many of those particles are circulating.
Under 150: the reference range, not a target
MedlinePlus lists under 150 mg/dL as a healthy fasting category. Current guidance does not establish a special longevity target below that.
Routine lipid testing does not always require fasting. A joint consensus statement from the European Atherosclerosis Society and the European Federation of Clinical Chemistry and Laboratory Medicine, led by Copenhagen University Hospital’s Børge Nordestgaard, found that triglycerides rise by an average of at most about 26 mg/dL after ordinary meals. The authors recommended nonfasting lipid profiles for routine use. For nonfasting samples, they set the flag at 175 mg/dL rather than 150.
The 2026 U.S. guideline permits fasting or nonfasting measurement for routine assessment and uses fasting confirmation in selected circumstances, including markedly elevated nonfasting triglycerides or suspected triglyceride disorders. The sample condition matters when comparing the result with a threshold.
150 to 499: a risk enhancer, not a diagnosis
Here the number is mainly a sign of cardiovascular risk. The Copenhagen City Heart Study followed about 14,000 Danish adults aged 20 to 93 for an average of 26 years. Compared with people whose nonfasting levels were below about 89 mg/dL, women at 443 mg/dL or higher had 5.4 times the adjusted risk of heart attack; for men the figure was 2.4. Total mortality also rose with triglyceride level in both sexes.
That’s an association. The authors interpreted higher nonfasting triglycerides as a marker of remnant lipoproteins that may promote atherosclerosis. Remnants are the partly emptied particles left over after triglyceride-rich lipoproteins unload fat into tissues.
The 2026 guideline first considers lifestyle and secondary causes—other conditions, medicines or circumstances that can raise triglycerides. It tailors recommendations about diet, alcohol, activity and weight to the person, especially when triglycerides are very high. MedlinePlus lists potential contributors including uncontrolled diabetes, kidney or liver disease, thyroid conditions, alcohol use disorder and certain medicines.
For people without established cardiovascular disease, the guideline uses a risk calculator called PREVENT in adults age 30 to 79 to guide clinician–patient decisions. Its public summary says ApoB can refine risk particularly when triglycerides exceed 200 mg/dL, when diabetes is present or when LDL cholesterol is already below 70 mg/dL. Elevated triglycerides can make a standard LDL value less representative of the total number of particles that can contribute to artery plaque.
What distinguishes a triglyceride risk category from an explanation of why the level is elevated?
At 500 to 999, why does the pancreas enter the conversation?
Acute pancreatitis is a painful and sometimes dangerous inflammation of the pancreas. In a Copenhagen analysis of roughly 117,000 adults, Simon Pedersen, Børge Nordestgaard and colleagues found higher triglycerides were associated with higher pancreatitis risk, even below the traditional danger zone. Absolute event rates remained low in this population study; the association is not an individual forecast.
The 2026 guideline and National Lipid Association review treat this range as a reason for prompt assessment of secondary causes and a diet plan tailored to the person. They discuss drug treatment to lower triglycerides and pancreatitis risk, with particular emphasis on preventing pancreatitis at 1,000 mg/dL or more.
1,000 and above: pancreatitis prevention comes first
A 2026 National Lipid Association review by Vera Bittner and Carol Kirkpatrick emphasizes that pancreatitis prevention becomes a major concern at 500 mg/dL and especially at 1,000 mg/dL. Dietary treatment at these levels is specialized and warrants clinician and registered-dietitian guidance rather than a generic low-fat instruction.
A newer class of drugs targets apolipoprotein C-III, a protein that slows removal of triglycerides from the blood. In the CORE-TIMI 72a and CORE2-TIMI 72b trials, adults with severely elevated triglycerides received monthly olezarsen or placebo. Olezarsen substantially lowered triglycerides and reduced acute-pancreatitis events compared with placebo. The effects differed by trial and dose; the exact results are below.
The trade-offs were real. Liver-enzyme elevations and low platelet counts were more common at the 80 mg dose. The researchers also reported that liver fat rose with the dose. Ionis Pharmaceuticals, the drug’s maker, funded both trials. The FDA expanded approval of olezarsen (Tryngolza) on June 24, 2026, for use with diet to reduce triglycerides and acute-pancreatitis risk in adults with severe hypertriglyceridemia, defined there as fasting levels of at least 500 mg/dL. The approval does not claim prevention of heart attacks or longer life.
How does the outcome under discussion change across the triglyceride ranges?
Does the triglyceride number change as you age?
Not in a straight line. Very little about this number is. In the Tromsø Study in Norway, which measured nonfasting triglycerides in about 21,000 adults aged 40 and older, men had higher levels than women. Among men, triglycerides were lower at older ages. Postmenopausal women had significantly higher levels than premenopausal women, and body mass index was linked to higher triglycerides in both sexes. That menopause shift is one reason lipid panels come up in menopause and heart-disease discussions.
In the ARIC study, Baylor researchers followed about 6,400 older adults for up to six years. A specialty measure of triglyceride carried in LDL particles predicted cardiovascular events after accounting for traditional risk factors. That research measurement is not the triglyceride value on a routine lab report.
MedlinePlus suggests testing about every 5 years for younger adults, every 1 to 2 years for middle-aged adults and yearly after 65. Your clinician may choose a different schedule.
What’s Interesting
For decades, the question was whether triglycerides cause heart disease. Genetics and trials have reframed it: the risk seems to travel with the number of ApoB-carrying particles. A drug can move the triglyceride number without moving that count much. It’s a bit like judging traffic by the amount of cargo instead of the number of trucks on the road.
The newest drugs show how narrow approvals can be. Olezarsen cut pancreatitis in people with severe elevations, a meaningful outcome in its own right, while leaving the cardiovascular question for later trials.
What This Means in Practice
For living longer and better, the 2026 guideline considers triglycerides alongside overall cardiovascular risk and the risk of pancreatitis. A change in the number alone does not establish a change in either outcome.
The big population findings here come from Danish and Norwegian adults, and the Tromsø data show levels differing by sex, menopause status and body mass index. The same number may carry different weight from one person to the next, which is part of why the guideline reads it alongside overall risk.
- Fasting status changes the comparison. The fasting reference range and the nonfasting flag are different.
- A surprising result can have several explanations. Alcohol, a large meal or uncontrolled blood sugar can raise it. The 2026 guideline uses fasting confirmation in selected circumstances; the need for confirmation does not erase its emphasis on prompt assessment of very high levels.
- Ask about secondary causes: thyroid, kidney and liver function, diabetes control and medications.
- Ask whether ApoB would refine risk particularly if triglycerides exceed 200 mg/dL, diabetes is present or LDL cholesterol is already low.
- Levels of 500 mg/dL or more change the clinical concern. The National Lipid Association review emphasizes pancreatitis prevention at this level, especially at 1,000 mg/dL or more; these findings warrant timely clinical assessment.
- Over-the-counter fish oil is different from prescription icosapent ethyl. Evidence about the prescription drug cannot establish the benefits of a shop-bought supplement.
A primary care clinician can interpret a lipid panel. A lipid specialist, preventive cardiologist or endocrinologist can help with persistent elevations over 500 or a suspected inherited disorder. A registered dietitian can build the diet plan the guideline describes.
Bottom Line
A fasting triglyceride level under 150 mg/dL is the standard healthy category. Persistent elevation calls for attention to lifestyle, secondary causes, ApoB-containing particles and overall cardiovascular risk. At 500 mg/dL and especially 1,000, pancreatitis risk changes the urgency; olezarsen now has an FDA indication for reducing triglycerides and acute-pancreatitis risk in severe hypertriglyceridemia. Two major modern fibrate trials in diabetes were neutral overall, while prescription icosapent ethyl reduced cardiovascular events in a selected high-risk population. None of this establishes lifespan extension from lowering triglycerides alone.
A NOTE FROM LONGEVITY365
We read research, consult expert perspectives and work to make complicated health information easier to understand. What you’re reading here reflects how we’ve interpreted and organized that information. It is educational content—not personal medical advice, diagnosis or treatment guidance.
We’re not perfect, and neither is the available research. Evidence changes, new studies emerge and what’s appropriate for one person may not be appropriate for another.
Use this article as a starting point for your own research and conversations with qualified professionals. Always talk with your doctor or another trusted healthcare professional before making decisions that could affect your health, particularly if you take medications, are receiving treatment, have existing health conditions, are pregnant or have other circumstances that could affect what’s appropriate for you.
Reader Questions
A few questions to carry into the comments or your next conversation. Please leave out identifying or personal medical details.
- 01What part of "Triglycerides and Healthy Aging" surprised you most, or made you want to ask a better question?
- 02Which distinction in the article would be most useful to carry into everyday life?
- 03What would you want Humanic Blue to unpack next from this topic?
Extra Insights & Sources
The evidence summaries and linked sources behind this article.
What We Know
Triglycerides above 150 mg/dL fasting, or 175 nonfasting, are a recognized cardiovascular risk enhancer. Very high levels raise pancreatitis risk. Established.
Genetics points to the particles, not the fat itself. A Mendelian randomization study in JAMA, led by Brian Ference with 654,783 participants, compared gene variants that lower triglycerides with variants that lower LDL. Per 10 mg/dL lower ApoB, both carried similar lower coronary risk. Once ApoB was accounted for, triglycerides themselves no longer predicted risk. The authors concluded that the expected coronary benefit tracked the absolute change in ApoB. Supported (genetic evidence). Several authors reported industry consulting fees.
The trial results below use hazard ratios (HRs) to compare how quickly events occur among people still at risk at a given point during follow-up. An HR of 1 means no difference between groups; below 1 means a lower hazard and above 1 a higher hazard. These are relative comparisons, not the percentage of people who will experience an event.
The drug trials line up with that. In PROMINENT, 10,497 people with type 2 diabetes took pemafibrate for a median 3.4 years. It cut triglycerides by 26.2% but nudged ApoB up 4.8%. Cardiovascular events were no lower (HR 1.03), and kidney problems and blood clots were more common. The trial was funded by Kowa. In ACCORD Lipid, adding fenofibrate to simvastatin in 5,518 people with diabetes did not reduce events (HR 0.92, not significant).
The exception is REDUCE-IT, funded by Amarin. Among 8,179 statin-treated, high-risk patients with triglycerides of 135 to 499 mg/dL, 4 g/day of prescription icosapent ethyl lowered the primary event rate from 22.0% to 17.2%. Cardiovascular death was 4.3% vs. 5.2%. Atrial fibrillation hospitalization was more common (3.1% vs. 2.1%). The 2026 guideline gives it a weak recommendation, as a possible option in adults 50 and older with heart disease, or with diabetes plus another risk factor. Why this drug worked when mixed omega-3s didn’t is covered in Do Omega-3 Supplements Help You Live Longer?
What We Don’t Know
- Whether lowering triglycerides extends human lifespan. Unknown. The trials cited here do not establish a survival extension, and PROMINENT and ACCORD Lipid did not reduce deaths.
- Whether olezarsen reduces heart attacks or strokes. Unknown. Its approval rests on triglyceride and pancreatitis outcomes.
- Why icosapent ethyl reduced events when fibrates didn’t. Contested. REDUCE-IT’s mineral-oil placebo is still debated.
- Whether older-adult-specific targets would help. Unknown. No guideline sets age-specific triglyceride goals.
Detailed trial results
CORE-TIMI 72a and CORE2-TIMI 72b. Across the two trials, 1,061 adults with severe hypertriglyceridemia received monthly olezarsen or placebo. At six months, researchers compared the groups’ percentage changes in triglycerides from their starting levels. The reduction was about 49 to 72 percentage points greater with olezarsen than with placebo, depending on the trial and dose. That is a difference between percentage changes; the triglyceride concentration itself is measured in mg/dL, not percentage points. Acute pancreatitis was less frequent with olezarsen: the rate ratio of 0.15 means the group’s event rate was about 15% of the placebo rate across the trials, not that an individual had a 15% chance of pancreatitis. Dose-related liver-enzyme elevations, low platelets and increased liver fat are discussed in the story above, alongside Ionis funding and the scope of FDA approval.
Triglycerides still carry signal later in life. In the ARIC study, Baylor College of Medicine researchers followed 6,359 adults with a mean age of 75.8 for up to six years. Triglyceride carried in LDL particles (LDL-TG) independently predicted cardiovascular events after adjustment for traditional risk factors (HR 1.72 per log unit). Here, a log unit is a step on the logarithmic scale the researchers used for LDL-TG: it represents proportional changes in concentration rather than equal mg/dL increases. A one-unit increase on that scale was associated with a 72% higher relative hazard of cardiovascular events in the model. It is not a result per 1 mg/dL, nor a prediction of one person’s event probability. Those are specialty research measures, not standard lab tests.
Acute pancreatitis is a painful and sometimes dangerous inflammation of the pancreas. In a Copenhagen analysis of 116,550 adults, Simon Pedersen, Nordestgaard and colleagues found the risk rose well before the traditional danger zone. At 443 mg/dL or higher, the adjusted hazard ratio for acute pancreatitis was 8.7 compared with people below 89 mg/dL. The HR of 8.7 is a relative comparison between those groups. In absolute terms, the higher-triglyceride group had 12 events per 10,000 person-years. Person-years add together everyone’s time under observation: 10,000 person-years could mean 10,000 people followed for one year or 2,000 followed for five years. This describes the observed group event rate, not one person’s chance of pancreatitis over the next year.
Sources
- MedlinePlus. Triglycerides test. U.S. National Library of Medicine patient reference. Supports fasting categories, potential secondary causes and general testing context. These are reference categories, not individualized treatment targets.
- Blumenthal RS, et al. 2026 guideline on the management of dyslipidemia: Top Things to Know. American Heart Association official summary. Supports PREVENT ages 30–79, statins as the pharmacologic foundation for persistent elevation, ApoB use particularly above 200 mg/dL and pancreatitis-focused treatment especially at 1,000 mg/dL or more.
- Nordestgaard BG, et al. Fasting is not routinely required for determination of a lipid profile. European Heart Journal. 2016. European consensus drawing on large observational datasets. Supports routine nonfasting testing, the average post-meal change and the 175 mg/dL nonfasting flag; consensus guidance rather than an outcomes trial.
- Nordestgaard BG, Benn M, Schnohr P, Tybjærg-Hansen A. Nonfasting triglycerides and risk of myocardial infarction, ischemic heart disease, and death. JAMA. 2007. Copenhagen cohort of 13,981 adults followed for a mean 26 years. Supports graded associations with cardiovascular outcomes and mortality; observational and not proof that triglycerides themselves are the causal agent.
- Pedersen SB, Langsted A, Nordestgaard BG. Nonfasting mild-to-moderate hypertriglyceridemia and risk of acute pancreatitis. JAMA Internal Medicine. 2016. Copenhagen cohort of 116,550 adults. Supports graded pancreatitis association and low absolute rates; cannot determine an individual’s near-term risk.
- Bittner V, Kirkpatrick CF. Lifestyle and pharmacologic interventions for adults with hypertriglyceridemia. Journal of Clinical Lipidology. 2026. Professional review interpreting the 2026 guideline. Supports the increasing pancreatitis focus at 500 and especially 1,000 mg/dL; author disclosures are reported in the paper.
- Marston NA, et al. Olezarsen for severe hypertriglyceridemia. New England Journal of Medicine. 2026. Two randomized trials totaling 1,061 adults, six-month primary triglyceride endpoint. Supports dose-specific triglyceride reductions, fewer pancreatitis events and safety findings. Ionis funded the trials; cardiovascular outcomes were not established.
- U.S. Food and Drug Administration. FDA approves first treatment shown to reduce acute-pancreatitis risk in adults with severe hypertriglyceridemia. June 24, 2026. Supports the current expanded Tryngolza indication, severe-hypertriglyceridemia definition, trial population and common adverse reactions. It does not claim cardiovascular or lifespan benefit.
- Njølstad I, et al. Nonfasting triglycerides in the Tromsø Study. 2023. Cross-sectional Norwegian study of 20,963 adults age 40 or older. Supports age-, sex-, menopause- and body-mass associations; cross-sectional and population-specific.
- Saeed A, et al. Lipoprotein triglyceride content and cardiovascular risk in older adults. 2021. ARIC cohort analysis of 6,359 older adults followed up to six years. Supports the research finding for LDL-carried triglyceride; the specialty measure is not routine serum triglycerides.
- Ference BA, et al. Association of triglyceride-lowering variants with coronary risk. JAMA. 2019. Mendelian-randomization analysis of 654,783 participants. Supports risk scaling with ApoB particle change; genetic proxies are not equivalent to prescribing a drug, and several authors disclosed industry relationships.
- Das Pradhan A, et al. Triglyceride lowering with pemafibrate to reduce cardiovascular risk. New England Journal of Medicine. 2022. PROMINENT randomized 10,497 adults with type 2 diabetes for median 3.4 years. Triglycerides fell without fewer cardiovascular events; renal and thromboembolic adverse events were higher. Kowa funded the trial.
- ACCORD Study Group. Effects of combination lipid therapy in type 2 diabetes mellitus. New England Journal of Medicine. 2010. Randomized 5,518 participants with diabetes. Adding fenofibrate to simvastatin did not reduce the primary cardiovascular outcome overall; subgroup findings were not definitive.
- Bhatt DL, et al. Cardiovascular risk reduction with icosapent ethyl for hypertriglyceridemia. New England Journal of Medicine. 2019. REDUCE-IT randomized 8,179 statin-treated high-risk patients for median 4.9 years. Supports lower cardiovascular event rates and higher atrial-fibrillation hospitalization; Amarin funded the trial and the mineral-oil comparator remains debated.
Photo credits
Images from Pexels.
- featured: Photo by https://kaboompics.com/ — original Pexels photo.
- inline-1: Photo by Vitaly Gariev — original Pexels photo.
- inline-2: Photo by beyzahzah — original Pexels photo.
Leave a Reply